The presence of this mutation is in fair agreement with IHC positivity of the tumor cells for FOXL2 expression, which allows for application of the FOXL2 expression as a surrogate IHC marker for the FOXL2p.C134W mutation. The gene discussed is FOXL2; the disease is neoplasm.